Executive Summary

Executive Summary

Overview – 1/22/2021

OyaGen has its origins in the science of gene editing enzymes that affect the genetic readout of cells and viruses, through the academic work of Dr. Harold C. Smith, University of Rochester, Rochester, NY (http:/dbb.urmc.rochester.edu/index.htm). Founded by Dr. Smith in 2003, OyaGen, Inc. holds exclusive Intellectual Property (IP) licensed from Thomas Jefferson University and numerous self-generated IP on the Company’s platform of drug targets and antiviral lead compounds. In 2010 OyaGen began drug discovery work on oral deliverable anti viral compounds for HIV based on a novel viral drug target and methodology that distinguished the Company’s approach from all others in the pharmaceutical space. We are the only commercial effort drugging the HIV Vif protein thereby enabling natural (innate) immunity through host cell restriction factors to effectively neutralize all clades and strains of HIV. Lead compounds under development have been tested and acknowledged for their potential as first-in-class drug candidates by the Federal Government (NIAID). In addition, the Company has a platform technology that has enabled advanced lead identification for SARS-CoV2, MERS, Ebola and Lassa virus whose safety is known in human subjects and preclinical animal studies.

Coronavirus
OyaGen developed Oya1 in collaboration with NIH/NIAID as a highly potent compound that prevents the spread of infection of Coronaviruses, Ebola, Lassa virus and Pox virus. OyaGen is seeking FDA approval for its patent-protected Oya1 in the treatment of COVID-1 and have completed preIND discussions with the FDA. Oya1 is significantly more effective in stopping live SARS2 and Ebola virus infections in the laboratory than Gilead Sciences’ Remdesivir® but in combination with Remdesivir®, markedly improved the antiviral efficacy of Remdesivir® enabling maximal virus stopping power with lower doses for both drugs. Human safety has already been evaluated by the NCI in phase I and phase II clinical trials in the 1960s when Oya1 was evaluated as a candidate for cancer treatment. Oya1 had no serious adverse side effects in these studies when tested in 88 human subjects over a range of doses and dose intervals but was abandoned due to a lack of efficacy against various cancers. Oya1 is therefore a near term treatment solution addressing the unmet need for a highly effective medical countermeasure for people who become infected with SARS-CoV-2 and for immunocompromised patients who cannot benefit from COVID immunization.

Coronavirus (CoV) infections with higher than expected morbidity and mortality have emerged three times in the past two decades (SARS1, MERS and SARS2). Global biomedical science is only now racing to identify vaccines for what has now been predicted to be a disease with annual reoccurrence. COVID-19 vaccines have been developed but their global deployment has faced challenges and their efficacy and potential for establishing herd immunity is hotly debated. The international focus on COVID-19 vaccine development for prevention has left an unmet need for highly active, antiviral therapies for treating people who become infected and need highly active antiviral therapies to prevent disease progress, serious side effects or death. Laboratory testing performed in collaboration with NIAID suggested that Oya1 may be the most effective treatment for COVID-19 to date.

The data support that Oya1 alone or in combination with Remdesivir® (and potentially other treatment regimens including monoclonal antibodies (Mab), convalescent serum and/or corticosteroids or other immune modulators) holds the potential to halt COVID-19 and the now readily apparent threat from new viral strains that may have greater virulence or resistance to Mab therapeutics and current vaccines.

OyaGen owns the patent rights to TNX-3500 (aka sangivamycin). Specifically, OyaGen has seven patents pending for this highly potent compound that prevents the spread of infection by Coronaviruses, Ebola, Lassa virus and Pox virus. The compound was taken through late-stage preclinical development by OyaGen prior to exclusively licensing it to Tonix Pharmaceuticals Inc, a clinical stage company who will develop TNX-3500 for clinical trials and commercialization. TNX-3500 has been safely administered to nonhuman primates and humans in the 1960’s during the war on cancer but was abandoned as being ineffective against cancer. TNX-3500 is a broad-spectrum antiviral and has excellent drug-like ADMET properties and higher potency relative to remdesivir in live virus studies. TNX-3500 antiviral activity is additive with remdesivir when the drugs are used in combination. TNX-3500 potential as a preventative for viral infections is suggested by its long half-life in tissues. TNX-3500 holds potential as a much needed, life-saving therapeutic approach for those who cannot benefit from a vaccine or will not take a vaccine.

HIV and Ebola Market
HIV-1: OyaGen will soon complete IND-enabling studies and engage the FDA in preIND discussions for Irino-L, a patent-protected, first-in-class antagonist of the HIV-1 Vif protein that protects the APOBEC innate immune system and blocks HIV replication through gene editing. Formulation for oral dosing is the Company’s priority. OyaGen has developed Irino-L through grants and contract research with NIAID and has a series of follow on 2 Vif antagonists in development. Irino-L not only has therapeutic potential but holds the potential to reduce viral reservoir formation as part of a strategy for a cure and prevention.

Irino-L and Vif antagonist will have significant market pentation because there remains a significant health care unmet need due to new infections and 30+ million HIV/AIDS patents worldwide. The drug market is expected to continue to show sustained growth despite advances in controlling the progress of the disease (Cowen & Company). The incidence of HIV continues to grow at a double-digit rate in developed markets according to the U.S. Center for Disease Control. Patient treatment remains low. Approximately 30% of UScitizens infected with HIV are unaware they are HIV positive While treated patients have longer survival, the failure rates for current frontline therapies are 10% and ultimately the virus’s ability to mutate continues to demand new drugs. Each first-in-class HIV drug has achieved blockbuster annual sales (Cowen & Co.). In recent years the Pharma pipeline for new class of HIV therapeutics have dried up largely due to reduction in R&D expenditure. OyaGen preclinical development for a first-in-class treatment is unique in the global effort has significant potential for treatment, prevention and cure.

OyaGen has in late-stage preclinical development a unique therapeutic lead for HIV/AIDS that is 14-16 months from a pre-IND meeting with the FDA. Despite several FDA approved treatments, HIV remains a significant health care issue with >60 million people worldwide affected. The emergence of drug resistant HIV strains, enhanced by inconsistent access to a continuum of care continues to promote the spread HIV globally. The incidence of HIV continues to grow at a double-digit rate according to the U.S. Center for Disease Control. Approximately 30% of US citizens infected with HIV are unaware they are HIV positive. While treated patients have longer survival, the failure rate for current frontline therapies is 10% and ultimately the virus’s ability to mutate continues to demand new drugs. Consequently, the international drug market is expected to continue to show sustained growth despite advances in controlling the virus for those patients with access to treatment (Cowen & Co.). Our current preclinical efforts have shown our leads to be broadly neutralizing of all strains of HIV and additive in efficacy with all commercial highly active anti-HIV therapeutics. We have developed the chemical path with CROs for producing pure compounds and are developing oral formulations that will enable sustained blood levels for once-a-day dosing.

Each first-in-class HIV drug has achieved blockbuster annual sales (Cowen & Co.). In recent years the Pharma pipeline for new classes of HIV therapeutics has dried up largely due to reduction in R&D expenditure. PimStrategus Professional Valuation Services research suggested that while OyaGen’s lead compound has great potential in HIV therapeutics and will be effective against new strains of HIV that may be resistant to current treatments, it has high potential for a block-buster status in the areas of HIV prevention (PrEP) and HIV cure. In that regard, OyaGen has initiated in vitro studies in reservoir cells assessing the potency to neutralize viremia associated with reservoir cell reactivation as proof-of-concept that OyaGen’s lead compound could be part of a functional cure strategy.

Ebola: Oya1 originally was first discovered as broad microbicide and an Ebola antiviral in collaboration with NIAID. This work was recently published (Bennett et al., (2021) ‘A Novel Ebola Virus VP40 Matrix Protein-Based Screening for Identification of Novel Candidate Medical Countermeasures’ Viruses Viruses 13 https://doi.org/10.3390) and is patent protected. The published data show that Oya1 is markedly more effective than Remdesivir® but has significant virus stopping capability alone or in combination with Remdesivir®. Clinical trials showed that Mab therapy had greatest therapeutic value in treating Ebola. Vaccination strategies for Ebola and Remdesivir® were minimally effective for people infected with Ebola who already have symptoms. The unmet need is that protection through immunization takes 21 days but the virus kills in 14 days. When an Ebola vaccine becomes available, it may prevent the spread of Ebola to those who are immunized but it will not prevent transmission or death of persons within the disease epicenter who are not immune. Mab production and distribution are costly and require special infrastructure. OyaGen will address the unmet need for highly active antiviral therapies that are low in cost of production and distribution. OyaGen’s lead is intended for oral or ballistic deliver for people who become infected.

OyaGen Key Assets
OyaGen has discovered and patented first-in-class lead (Irino-L) that enables our innate immunity against HIV as a treatment with curative potential for HIV/AIDS and patented best-in-class Oya1 as candidate treatment for infections due to Coronavirus, Ebola virus, Lassa virus and Pox virus. In addition, the Company’s laboratory, platform technology and broad technical knowhow has enabled the development of a cancer drug discovery platform based on gene editing enzymes. There are more than 20 scientist working on the Company’s projects through established contract research and co-development relationships with NIH/NIAID, Southern Research, ImQuest Biosciences, Cayman Chemical. These scientists support viral testing, medicinal chemistry, cGMP compound production. OyaGen works closely with regulatory consultants and clinical CROs. This team is
accelerating the preclinical medicinal chemistry, ADME and safety testing needed for filing an IND for our HIV lead and the Coronavirus and Ebola antiviral lead.

Drs. Harold C. Smith, Founder and CEO, Ryan P. Bennett, CSO and Laboratory director and Jason D. Salter, Scientist, lead the Company’s drug discovery and drug development efforts. The Company currently occupies a 3,200 sq. ft. state-of-the-art laboratory within the Rochester BioVenture Center in Rochester NY. A broad range of advanced instrumentation, controlled environments, small molecule libraries in a BLS2+ facility enable in-cell and cell-free assay development, infectivity and other functional endpoint analyses and high throughput screening at our current rate of 5,000 compounds/assay/day. We maintained a low overhead and sustainable footprint through association with contract laboratories, both federal and private, that perform specialized testing and validation services.

The Company has a management team and external advisors with collectively over 100 years of experience in Biopharma and the Life Sciences. Dr. David Ho, CEO of the Aaron Diamond AIDS Research Center at Rockefeller University (NYC) who was a Time Magazine Man of the Year and one of the world’s leading HIV authorities serves on the Scientific Advisory Board (SAB). Dr. Roscoe Moore, former Assistant Surgeon General and OyaGen Board member advises the company on worldwide health priorities, Dr. James Cummings, president of ICON and Dr. Richard Ogden, former Agouron/Pfizer scientist and executive. OyaGen’s Board  member advises the company on pharmaceutical industry trends. Amy Fix, MS. MBA, RAC and VP of regulatory affairs with Arcellx, Inc serves as the company’s regulatory consultant, Thomas Fitzgerald, Esq serve as Chief Operations Officer and legal consultant; Andrew Gonsalves, Esq with FisherBroyles serves as patent attorney consultant and Kimberly Staffieri, financial and controller services.

OyaGen maintains an informative website that provides more detailed information about HIV and the approach that the Company used to advance its range of therapeutics. (https://oyageninc.com) with two medical animations describing the HIV therapeutic and cure approaches (searchable in YouTube under Oyageninc). The Company also has a Wikipedia page and is on Facebook. Inquiries should be directed to:

Dr. Harold C. Smith, Founder, CEO, President
OyaGen, Inc., 77 Ridgeland Road, Rochester, NY 14623 USA
Cell: 1 (585) 697-4351; E-mail: hsmith@oyageninc.com